Ipsen's Dysport Shows Superior Duration Over Botox in First Head-to-Head Spasticity Trial
核心洞察
The Phase IV DIRECTION trial represents the first prospective, head-to-head comparison between Dysport and Botox in adults with upper limb spasticity, involving 464 patients across 72 sites.
Dysport demonstrated non-inferior safety compared to Botox with lower adverse event rates (20.3% vs 23.0%) and achieved significantly longer duration of effect (14.2 vs 13.8 weeks).
The findings address critical unmet needs as over 80% of patients experience breakthrough symptoms between injection cycles and more than 70% express need for longer-lasting treatment.
Ipsen announced results from the landmark DIRECTION trial, the first prospective head-to-head Phase IV study comparing Dysport (abobotulinumtoxinA) to Botox (onabotulinumtoxinA) in adults with upper limb spasticity. The randomized, double-blind, crossover trial involving 464 patients demonstrated that Dysport achieved both non-inferior safety and superior duration of effect compared to Botox.
The study met its primary safety endpoint, with Dysport showing a treatment-emergent adverse event rate of 20.3% versus 23.0% for Botox (adjusted difference -2.7%, 80% CI: -6.2%, 0.9%). More significantly, patients treated with Dysport experienced longer-lasting symptom control, with a duration of effect of 14.2 weeks compared to 13.8 weeks for Botox (adjusted difference favoring Dysport, 80% CI: 0.2, 5.9; p=0.17 with significance threshold p=0.20).
Addressing Critical Treatment Gaps
The DIRECTION trial addresses decades-long evidence gaps in spasticity treatment by providing the first direct comparative data between these widely used botulinum toxin therapies. According to published research cited in the study, over 80% of patients experience breakthrough symptoms between injection cycles, and more than 70% express a need for longer-lasting treatment.
"Today, for the first time, we have comparative evidence that distinguishes the performance of two widely used botulinum toxin treatments in patients with spasticity," said Dr. Alberto Esquenazi, DIRECTION Principal Investigator. "These findings are based on a rigorously controlled study design and contribute meaningful data for clinicians, strengthening the evidence available for the use of botulinum toxin therapies in people with spasticity."
Rigorous Study Design
The DIRECTION trial (NCT04936542) enrolled 464 adults with upper limb spasticity across 72 sites in the USA, France, and Canada. Participants had an average age of 57 years, with two-thirds being male and most having spasticity due to stroke. Each participant received one treatment cycle with each toxin using standardized, instrument-guided techniques to ensure fairness and comparability.
The trial controlled for multiple factors that could affect treatment outcomes, including volume, dilution, dose, muscles treated, and guidance techniques. The study was specifically powered to detect differences in safety (primary endpoint), duration of response (key secondary endpoint), and functional outcomes.
Clinical Significance
Evidence of longer duration was consistent across most demographic and clinical subgroups, which is particularly important given the high prevalence of breakthrough symptoms between treatments. Upper limb spasticity can significantly impair function, mobility, and quality of life, with botulinum toxin type A injections serving as a recommended first-line treatment.
"Ipsen is committed to generating robust clinical evidence that supports scientific understanding and real-world practice," said Sandra Silvestri, PhD, MD, Chief Medical Officer at Ipsen. "In spasticity, the durability of treatment response plays a critical role in patients' function, mobility and quality of life. The DIRECTION data provides further support that Dysport can delay breakthrough symptoms with a well-established safety profile."
Treatment Background
Dysport is an injectable botulinum neurotoxin type A product derived from Clostridium bacteria that inhibits nerve impulse transmission and reduces muscular contractions. The treatment has marketing authorization in approximately 90 countries, with more than 30 years of clinical experience and over 18 million treatment years of patient experience.
The findings were presented as a late-breaking session at the International Society of Physical and Rehabilitation Medicine (ISPRM) world congress in Vancouver on May 19, 2026, marking a significant milestone in spasticity treatment research.